CRP and heart failure: In the REDHART (Recently Decompensated Heart Failure Anakinra Response Trial), NYHA II-III HF patients with recently decompensated HF showed significantly reduced CRP levels (−3.4 mg/L from baseline [−66%], p = 0.011) and improved peak VO2 from baseline (p = 0.009) with 12 weeks of anakinra treatment.